Oragenics secures CQDM funding for Covid-19 vaccine antigen development
Pharmaceutical Technology
JUNE 6, 2023
Oragenics has secured funding from the Canadian bioresearch consortium CQDM to develop a variant-agnostic protein antigen for use in its Covid-19 intranasal vaccine. In March 2023, Oragenics and Inspirevax entered an exclusive global licence deal to develop the former’s lead intranasal Covid-19 vaccine candidate, NT-CoV2-1.
Let's personalize your content